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ARTD1 (PARP1) is a key enzyme involved in DNA
repair through the synthesis of poly(ADP-ribose)
(PAR) in response to strand breaks, and it plays
an important role in cell death following excessive
DNA damage. ARTD1-induced cell death is associ-
ated with NAD+ depletion and ATP loss; however,
the molecular mechanism of ARTD1-mediated en-
ergy collapse remains elusive. Using real-time meta-
bolic measurements, we compared the effects of
ARTD1 activation and direct NAD+ depletion. We
found that ARTD1-mediated PAR synthesis, but not
direct NAD+ depletion, resulted in a block to glycol-
ysis and ATP loss. We then established a prote-
omics-based PAR interactome after DNA damage
and identified hexokinase 1 (HK1) as a PAR binding
protein. HK1 activity is suppressed following nu-
clear ARTD1 activation and binding by PAR. These
findings help explain how prolonged activation of
ARTD1 triggers energy collapse and cell death,
revealing insight into the importance of nucleus-to-
mitochondria communication via ARTD1 activation.
INTRODUCTION
The human genome encodes 17 poly(ADP-ribose) polymerase
(PARP) or ADP-ribosyltransferase diphtheria toxin-like (ARTD)
proteins that are involved in regulating a variety of cellular pro-
cesses including DNA damage signaling and repair, chromatin
remodeling, transcription, epigenetic gene regulation, mitosis,
and differentiation (Hassa et al., 2006). All of the catalytically
active members of the ARTD/PARP family consume NAD+ toCell Recatalyze ADP-ribosylation of their target substrates but are clas-
sified as mono- or poly-(ADP-ribosyl) transferases depending
on their ability to transfer monomers or polymers of ADP-ribose
(Hottiger et al., 2010). In particular, poly(ADP-ribosyl)ation is
known for its switch-like effects on acceptor proteins by virtue
of its high charge density and steric hindrance. As a conse-
quence, this posttranslational modification can activate or inhibit
protein functions, disrupt or promote protein-protein interac-
tions, or facilitate protein subcellular relocalization (Hottiger
et al., 2010).
ADP-ribosyltransferase diphtheria toxin-like 1 (ARTD1 or
PARP1) primarily functions as a key enzyme of the base excision
repair (BER) and single-strand break repair (SSBR) pathways
(Almeida and Sobol, 2007). ARTD1 participates in additional
DNA repair pathways such as nonhomologous end-joining
(NHEJ), nucleotide excision repair (NER), in sensing and repair-
ing DNA double-strand breaks and is suggested to participate
in the excision step during mismatch repair (De Vos et al.,
2012). The participation of ARTD1 in these DNA repair pathways
depends on its ability to detect and bind to DNA single-strand
breaks with high affinity (Langelier et al., 2012). In BER, a strand
break is a normal repair intermediate, which is formed following
hydrolysis of the DNA backbone by an apurinic/apyrimidinic
endonuclease, APE1 (Almeida and Sobol, 2007; Svilar et al.,
2011), triggering ARTD1 activation. Upon activation, ARTD1 syn-
thesizes poly-(ADP-ribose) (PAR) that functions as a mechanism
of chromatin decondensation and generates a loading platform
for the recruitment of the BER machinery to the lesion site,
including proteins such as X-ray repair complementing defective
repair in Chinese hamster cells 1 (XRCC1), poly (ADP-ribose)
glycohydrolase (PARG) and DNA polymerase b (Polß; Schreiber
et al., 2006; Svilar et al., 2011). Successful recruitment of the
downstream BER proteins facilitates repair of the strand break,
suppressing further ARTD1 activity and PAR synthesis (Masson
et al., 1998; Tang et al., 2010).ports 8, 1819–1831, September 25, 2014 ª2014 The Authors 1819
Conversely, unrepaired DNA breaks, resulting from exces-
sive genotoxin exposure and/or from DNA repair defects, leads
to persistent ARTD1 activation and cell death (Gottipati et al.,
2010; Juarez-Salinas et al., 1979; Tang et al., 2010). Uncon-
trolled or excessive activation of ARTD1 is responsible for
numerous pathological outcomes including streptozotocin-
induced pancreatic beta-cell death and the onset of diabetes
(Burns and Gold, 2007; Masutani et al., 1999; Pieper et al.,
1999) as well as tissue injury from cerebral and myocardial
ischemia (Eliasson et al., 1997; Endres et al., 1997; Pieper
et al., 2000). In these and other mouse model studies, ARTD1
activation-induced tissue injury results from the accumulation
of DNA repair intermediates (Calvo et al., 2013).
Cell death due to ARTD1 activation was originally suggested
to involve energy metabolite (NAD+ and ATP) depletion (Berger,
1985; Berger et al., 1983; Jacobson et al., 1980). However, the
molecular mechanisms underlying ARTD1 hyperactivation-
induced ATP depletion and the resulting cell death are unre-
solved. Confounding this issue, cell type and in particular cellular
proliferation status, has yielded widely disparate observations.
In astrocytes, cytosolic NAD+ depletion resulting from ARTD1
activation is suggested to trigger a glycolytic block that can be
rescued by NAD+ or tricarboxylic acid (TCA) cycle substrates,
such as a-ketoglutarate and pyruvate (Ying et al., 2002, 2003).
Neuronal cell death from ARTD1 activation is triggered by unreg-
ulated PAR synthesis, termed parthanatos (Andrabi et al., 2008)
and has been suggested to play a role in multiple experimental
and physiopathological scenarios, including stroke, diabetes,
inflammation, and neurodegeneration. Some reports demon-
strate a direct link between ARTD1 hyperactivation and mito-
chondrial dysfunction, notably through the loss of NAD+ that
precedes the induction of the mitochondrial depolarization and
mitochondria outer membrane permeability transition (Alano
et al., 2004; Cipriani et al., 2005). In contrast, in apoptosis-defi-
cient cells, it is suggested that only cells relying on glycolysis
are sensitive to DNA damage-mediated ARTD1 hyperactivation
and necrotic cell death (Zong et al., 2004).
Herein, we tested the hypothesis that the glycolytic block and
loss of ATP induced by DNA damage-induced ARTD1 activation
is distinct from the resulting loss of NAD+. In addition, we demon-
strate that ARTD1 activation and the resulting synthesis of PAR
facilitates the block to glycolysis via regulation/inhibition of
PAR binding proteins including the essential glycolytic enzyme
hexokinase 1 (HK1).
RESULTS
ARTD1 Activation Induced by DNA Repair Intermediates
Triggers Energy Metabolite Depletion in
Glioblastoma Cells
The acute cellular response to DNA alkylation damage is depen-
dent on the expression of the methyl-specific DNA glycosylase
MPG (also known as AAG or ANPG; Tang et al., 2010) and an
imbalance in BER protein expression can lead to an accumula-
tion of toxic DNA repair intermediates (Fu et al., 2012). To eval-
uate the cellular consequences of DNA damage-induced DNA
repair intermediates, we used a glioblastoma-derived cell line,
LN428, with low levels of MPG and the isogenic derivative1820 Cell Reports 8, 1819–1831, September 25, 2014 ª2014 The AuLN428/MPG overexpressing MPG (Figures S1A–S1D available
online).
Upon activation, ARTD1 transfers theADP-ribosyl unit of NAD+
to synthesize PAR and as a consequence, leads to the rapid
loss of total cellular NAD+. ARTD1 activation also leads to the
concomitant loss of ATP and the onset of necrosis (Ha and
Snyder, 1999; Tang et al., 2010). Exposure of LN428/MPG cells
to MNNG (5 mM) results in the loss of close to 90% and 70%
respectively, of total cellular NAD+ and ATP pools with no meas-
ureable metabolite depletion observed in the control LN428 cells
at this dose ofMNNG (Figures 1A and 1B). As expected, pretreat-
mentwith thePARP-inhibitors ABT-888 or BMN-673 significantly
rescues the MNNG-induced NAD+ loss in the LN428/MPG cells
(Figure 1C). Importantly, ARTD1 inhibition completely attenuates
the MNNG-induced loss of ATP in LN428/MPG cells (Figures 1D
and S1K). To further investigate the involvement of ARTD1
in NAD+ and ATP loss, we depleted ARTD1 expression using an
shRNA coupled with overexpressed MPG via viral transduction
of LN428 cells, as described in the Supplemental Experimental
Procedures. We verified ARTD1 knockdown and MPG over-
expression by RT-PCR and immunoblot (Figures S1G and
S1H). PAR synthesis in LN428/ARTD1-KD/MPG cells is largely
impaired (Figure S1H) after MNNG even at 10 mM, as compared
to LN428/MPG cells (Figure S1D). Importantly, LN428/ARTD1-
KD/MPGcells present no defect in NAD+ nor ATP levels following
MNNG treatment, demonstrating a direct role for ARTD1 in the
loss of energy metabolites (Figures 1C and 1D; gray bars).
Real-Time Analysis of ATP Levels in Glioblastoma Cells:
ARTD1 Activation-Mediated ATP Depletion Initiates in
the Mitochondria
ATP is generated in both the cytosol and the mitochondria via
glycolysis andoxidative phosphorylation, respectively. However,
classicalmeasurements of ATP levels lack subcellular specificity,
limiting the conclusions that canbedrawn. Tomonitor changes in
ATP levels indifferent compartmentsof living cells as a functionof
MNNG exposure, LN428 and LN428/MPG cells were transiently
transfected with FRET-based ATP sensors, specifically targeted
to the mitochondria (AT1.03m), cytosol (AT1.03c), or nucleus
(AT1.03n), which produce a YFP FRET signal upon ATP binding
(Imamura et al., 2009b). An increase of the CFP/YFP ratio
therefore indicates a loss of ATP bound to the FRET sensor.
Expression of the FRET-based ATP sensors showed the ex-
pected subcellular localization measured 48 hr post-transfection
(Figure S1I) and localization was not affected by DNA damaging
agent or PARP inhibitor treatment (not shown).
Forboth theLN428andLN428/MPGcells, a10-minutebaseline
FRET ratiowasdeterminedprior to theadditionofMNNG (5mM).A
low CFP/YFP ratio was observed prior to treatment suggesting
normal baseline ATP levels in all subcellular compartments,
consistent with whole cell metabolite measurements (Figure 1B).
The different subcellular compartments had slight differences in
the absolute starting CFP/YFP ratio and were normalized to 1 at
the baseline to compare changes between compartments (Fig-
ure S1J). Consistent with the whole cell ATP analysis, the CFP/
YFP ratio remains close to the baseline in all three subcellular
compartments for up to 60 min after MNNG exposure of the
LN428 cells (Figure 1E), indicating that any changes in subcellularthors
Figure 1. ARTD1 Hyperactivation Induced
byDNARepair Intermediates Triggers Ener-
getic Depletion in Glioblastoma Cells
(A and B) Global NAD+ (A) and global ATP (B) levels
in LN428 and LN428/MPG cells after 1hr treatment
with either media or 5 mMMNNG. The data shown
is the average of 3 independent experiments ± SD
and are reported as percentage of the untreated
control cell line (LN428): (A)****p < 0.0001 (B)
**p = 0.01.
(C and D) Global NAD+ (C) and global ATP (D)
levels in LN428/MPG cells (black bars) or in
LN428/ARTD1-KD/MPG cells (gray bar) after a 1hr
treatment with either media, 5 mM MNNG or 5 mM
MNNG after a pretreatment with ARTD1 inhibitors
ABT-888 or BMN673, as indicated. The data
shown is the average of three independent ex-
periments ± SD and are reported as percentage of
the untreated cells: (C) **p < 0.005, ***p = 0.0003,
(D) ****p < 0.0001, ***p < 0.001.
(E and F) FRET ratio calculated in the compart-
ments of LN428 cells (E) or LN428/MPG cells (F)
transfected with the indicated FRET sensors.
Images were acquired each minute. A ten-minute
baseline period was recorded before cells were
treated with 5 mM MNNG (orange arrow). FRET
traces shown are the mean of five to seven cells
(LN428) or seven to nine (LN428/MPG) ± SE.ATP due to the minimal PAR formation must be below the sensi-
tivity of the FRET sensors. However, exposure of the LN428/
MPG cells to MNNG results in a rapid and dramatic change in
the CFP/YFP ratio, in line with the observed loss of total cellular
ATP (Figures 1B and 1F) (see Movies S1–S3). Surprisingly, of the
three subcellular compartments, an increase in theCFP/YFP ratio
(and hence a loss of ATP) was first observed in the mitochondria.
TheMNNG-induced loss of ATP in themitochondria began12min
after the start of MNNG treatment, concomitant with the peak of
PAR production (Figures 1F and S1D) followed by a decrease in
both the cytosolic and nuclear ATP pools, beginning 24 min after
MNNG exposure (Figures 1F and S1I). In the whole cell ATP
analysis, the MNNG-induced loss of ATP in the LN428/MPG cells
was completely blocked when ARTD1 was inhibited or depleted
(Figure 1D). Similarly, pretreatment of LN428/MPG cells with
the PARP inhibitor was able to rescue the ATP loss in all three
subcellular compartments (Figures S1K and S1L). These resultsCell Reports 8, 1819–1831, Sepsupport an ARTD1-dependent signal that
provides a means of intracellular commu-
nication between the nucleus and the
mitochondria in response to genotoxic
stress.
Nuclear to Mitochondrial
Communication via ARTD1
Activation: DNA Damage-Induced
Defects in Glycolysis and Oxidative
Phosphorylation
It has been hypothesized that NAD+ con-
sumption by ARTD1 activation is causa-tive for the rapid depletion of cellular ATP. The kinetics of loss
of the mitochondrial, cytosolic, and nuclear ATP pools in
response to ARTD1 activation suggests that variations in the
total cellular level of NAD+ may signal from the nucleus to the
mitochondria by regulating NAD+-dependent enzymes critical
for ATP biosynthesis. To examine this, wemeasuredmultiple pa-
rameters of glycolysis and mitochondrial oxidative phosphoryla-
tion in live-cell conditions with the Seahorse XF24 extracellular
flux analyzer (SEFA), essentially as described (Qian and Van
Houten, 2010; Varum et al., 2011). This real-time, live-cell anal-
ysis allows a measure of DNA damage-dependent changes
in oxidative phosphorylation (oxygen consumption rate, OCR)
and glycolysis (extracellular acidification rate, ECAR). The
sequential addition of four metabolic inhibitors: oligomycin,
FCCP, 2-deoxyglucose, and rotenone allows the calculation of
four critical metabolic parameters: (1) the ATP-coupled OCR;
(2) the total mitochondrial reserve capacity (TRC), or maximaltember 25, 2014 ª2014 The Authors 1821
respiratory rate; (3) the basal ECAR, which corresponds to the
basal glycolytic rate; and (4) the oligomycin-induced ECAR.
As expected, the isogenic LN428 and LN428/MPG cell lines
have similar basal ECAR and OCR profiles (Figures 2A and 2B;
left), ideal for comparative analysis. Changes in glycolysis and
oxidative phosphorylation were then measured in response to
MNNG (1 hr, 5 mM) and in combination with ARTD1 knockdown
or inhibition by pretreatment with either ABT-888 or BMN-673. In
line with earlier reports using mouse astrocytes (Berger, 1985;
Ying et al., 2003), strong ARTD1 activation resulted in the com-
plete loss of glycolysis after MNNG treatment, leading to a
decrease of both basal and induced ECAR in LN428/MPG but
not in LN428 cells (Figures 2A and S2A). Consistent with our
hypothesis that the metabolic defects result from ARTD1 activa-
tion, ABT-888 or BMN-673 treatment prior to MNNG exposure
leads to a complete rescue of both basal and induced ECAR
in LN428/MPG cells (Figures 2C and S2A). Moreover, we show
that exposure of LN428/ARTD1-KD/MPG cells to MNNG does
not lead to a loss of glycolytic rate as seen in the LN428/
MPG cells (Figures 2F and S2D), providing further evidence
for the direct involvement of ARTD1 in this defect of cellular
metabolism.
Consistent with the observed loss of NAD+ and ATP in the
LN428/MPG cells in response to MNNG, we found that these
cells undergo a complete loss of TRC, with no change to the
ATP-coupled OCR (Figure 2B; right). The LN428 cells also pre-
sent with a partial yet significant loss (50%) of TRC in response
to MNNG treatment. To determine if the effects observed in
both cell lines was the sole result of ARTD1 activation and
NAD+ depletion, the identical analysis was performed with
ARTD1 inhibited by pretreatment with ABT-888 or BMN-673.
Interestingly, we observed a complete rescue of TRC in
LN428 cells upon ARTD1 inhibition (Figures 2E and S2C). These
data suggest that even a low level of ARTD1 activation (in the
case of LN428 cells and illustrated by the anti-PAR immunoblot;
Figure S1D) is able to affect the mitochondrial reserve capacity.
ARTD1 inhibition is also able to rescue the mitochondrial
reserve capacity defect of MNNG-treated LN428/MPG cells
(Figures 2D and S2B). To further investigate the role of
ARTD1 in MNNG-induced OCR defects, we submitted LN428/
ARTD1-KD and LN428/ARTD1-KD/MPG cells to the same
treatment and performed the same analysis. As expected,
we show that LN428/ARTD1-KD cells do not present the partial
defect observed in LN428 cells after MNNG treatment.
Expressing MPG in the LN428/ARTD1-KD cells (LN428/
ARTD1-KD/MPG) does not trigger a loss of TRC in response
to MNNG treatment such as that seen in the LN428/MPG cells
(Figure 2G). These results strongly suggest that cellular oxida-
tive phosphorylation, as measured by oxidative reserve capac-
ity, is extremely sensitive to ARTD1 activation. The same results
have been observed in HeLa cells treated with increasing doses
of MNNG, demonstrating that the MNNG induced metabolic
defects are not glioblastoma specific nor an artifact of MPG
overexpression, but applicable to multiple cell types (Figures
S2F–S2J). From these data, we hypothesize that ARTD1 activa-
tion acts as the initiating signal from the nucleus to mediate
suppression of both glycolytic and mitochondrial oxidative
phosphorylation activity.1822 Cell Reports 8, 1819–1831, September 25, 2014 ª2014 The AuNAD+ Depletion Is Not Sufficient to Decrease Glycolysis
or Cellular ATP Levels
One of the strongest phenotypes associated with ARTD1 activa-
tion is an acute loss of NAD+, with 90% of the cellular NAD+ con-
tent lost within 1 hour (Figure 1A). Therefore, a likely candidate
to signal ARTD1 activation in the nucleus to the metabolic
machinery in themitochondria is the change in overall NAD+ con-
tent. To test this hypothesis, we directly reduced NAD+ levels in
the absence of ARTD1 activation. To inhibit NAD+ biosynthesis,
LN428/MPG cells were treated with FK866, a selective small
molecule inhibitor of the essential NAD+ biosynthesis enzyme
nicotinamide phosphoribosyltransferase (NAMPT; Figure 3A;
Hasmann and Schemainda, 2003). After a 24 hr treatment with
FK866 (10 nM), the NAD+ pool decreased by approximately
75%, roughly equivalent to the NAD+ loss after ARTD1 activation
(Figure 3B). Surprisingly, however, ATP levels remained constant
and viability was not affected in LN428/MPGcells after treatment
with FK866 (Figures 3C and S3A).
Consistent with a role for NAD+ as a cofactor in mitochondrial
enzymatic reactions, FK866-treated cells displayed a significant
decrease in total mitochondrial reserve capacity (Figures 3D and
S3B). Surprisingly, NAD+ depletion by FK866 treatment had no
effect on either the basal or induced ECAR, unlike MNNG treat-
ment (Figures 3E and S3C). To demonstrate specificity and
selectivity of FK866, treated cells were also supplemented with
nicotinamide riboside (NR), a precursor that does not require
NAMPT for conversion to NAD+ (Figure 3A). NR was synthesized
and purified as described in the Supplemental Experimental
Procedures (Figure S4). As expected, NR pretreatment could
overcome the NAD+ depletion induced by FK866 (Figure 3F);
however, NR did not prevent the loss of NAD+ or ATP after
MNNG even at a 10-fold higher dose (Figures 3F and 3G).
Consistently, the FK866-induced loss of TRC is completely
rescued by NR (Figures 3H and S3D) but NR was unable to
rescue the OCR and ECAR defects in LN428/MPG cells treated
with MNNG (Figures 3H, 3I, S3D, and S3E). Yet, at low doses of
MNNG, NR pretreatment was able to partially rescue NAD+
levels (Figure S3F). Interestingly, this partial rescue was not suf-
ficient to overcome the OCR and ECAR defects (Figures S3G
andS3H), suggesting amore complex effect of ARTD1 activation
on cellular metabolism. The sensitivity of oxidative phosphoryla-
tion but not glycolysis to direct depletion of NAD+, suggests that
ARTD1-mediated consumption of NAD+ is a major contributor to
the DNA damage-induced loss of oxidative phosphorylation, but
inhibition of glycolysis occurs through another unknown mecha-
nism of ARTD1 activation.
PARG Knockdown Rescues the Glycolytic Defect in
MNNG-Treated Cells
The nucleo-cytoplasmic translocation of PAR has been exten-
sively described (Andrabi et al., 2006). As an example, it has
been demonstrated that the movement of PAR into the cytosol
triggers the release of the mitochondrial protein AIF upon binding
of PAR to the AIF PAR-binding motif (PBM; Yu et al., 2006). This
phenomenon has recently been shown to require the endo- and
exoglycohydrolase activities of PARG (Mashimo et al., 2013;
Wang et al., 2011; Yu et al., 2002). To investigate whether the
glycolytic defects observed herein are due to a release of PARthors
Figure 2. Mitochondrial Dysfunction following
Alkylating Agent-Induced ARTD1 Activation
(A and B) Seahorse extracellular flux analyzer (SEFA)
measurement of ECAR metabolic profile (A) or OCR
metabolic profile (B) in LN428 or LN428/MPG cells treated
with either media or MNNG (5 mM, 1 hr). Bar graphs rep-
resenting basal ECAR and oligomycin induced ECAR (A) or
ATP coupled OCR and total reserve capacity (TRC) (B) are
shown on the right. Traces shown are the mean of two
independent experiments in which each data point repre-
sents technical replicates of five wells each ± SE. Basal
and induced ECAR rates, ATP coupled OCR and TRC are
calculated using the average of 3 data points collected for
each metabolic inhibitor, ± SD (*p < 0.05).
(C and D) ECAR measurements (C) and OCR measure-
ments (D) in LN428/MPG cells treated with 5 mM MNNG
following pretreatment with media control or ARTD1
inhibitors ABT-888 or BMN-673 as indicated. Shown is
the mean of three independent experiments ± SD as
described above: (C)*p < 0.05 compared to media for
basal ECAR, Cp < 0.05 compared to MNNG for basal
ECAR, **p < 0.005 compared to MNNG for basal ECAR,
++p < 0.005 compared to media for induced ECAR,
Cp < 0.005 compared to MNNG for induced ECAR, +p <
0.01 compared to MNNG for induced ECAR; (D) *p < 0.05,
**p < 0.01.
(E) OCR measurement in LN428 cells treated with 5 mM
MNNG following pretreatment with media control or
ARTD1 inhibitor ABT-888. Shown is the mean of three in-
dependent experiments ± SD (***p < 0.0004 compared
to media control for TRC, **p < 0.002 compared to MNNG
for TRC).
(F and G) ECAR measurement (F) and OCR measurement
(G) for LN428/ARTD1-KD or LN428/ARTD1-KD/MPG cells
after treatment with media control or 5 mMMNNG. Shown
is the average of three independent experiments ± SD as
described above.
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Figure 4. Absence of PARG Rescues Loss of ATP and Glycolytic
Defects in LN428 Cells after High-Dose MNNG Treatment
(A and B) Global NAD+ (A) and global ATP (B) measured in LN428/scr and
LN428/PARG-KD cells after 1 hr exposure to increasing doses of MNNG.
Shown is the mean of three independent experiments (ns, nonsignificant; *p <
0.04 compared to media-treated LN428/scr cells; **p < 0.01 compared
to media-treated LN428/PARG-KD cells; +p < 0.005 compared to each
respective dose of MNNG in LN428/scr cells).
(C and D) Seahorse measurement of ECAR metabolic profile (C) and OCR
metabolic profile (D) of LN428/scr or LN428/PARG-KD cells treated with either
media or MNNG (1 hr) at 10 mM, 15 mM, and 20 mM. Shown is the mean of three
independent experiments ± SD (*p < 0.05).
Figure 3. NAD+ Depletion Does Not Alter Glycolysis in LN428/MPG
Cells
(A) Schematic of NAD+ biosynthesis from nicotinamide riboside (NR) and from
recycling after ARTD1 consumption of NAD+-releasing nicotinamide (NAM).
NAM is subsequently phosphorylated by nicotinamide phosphoribosyl trans-
ferase (NAMPT), an enzyme selectively inhibited by FK866.
(B and C) Global NAD+ (B) and global ATP (C) measurement in LN248/MPG
cells after 24 hr of treatment with media or FK866 (10 nM). The data shown is
the average of three independent experiments ± SD and are reported as
percentage of the untreated cells; (B)*p < 0.05.
(D) Seahorse measurement of the OCR metabolic profile was performed in
LN428/MPG cells treated with either media control or FK866 (10 nM) for 24 hr.
Shown is the mean of four independent experiments ± SD (**p < 0.01).
(E) Seahorse measurement of the ECAR metabolic profile was performed as
above. Shown is the mean of two independent experiments ± SD.
(F) Global NAD+ level in LN428/MPG cells after either media, NR (1 mM) or
FK866 (10 nM) with or without NR (1 mM) as a 24 hr pretreatment. Cells treated
by MNNG, and pretreated or not by NR, are incubated 1 hr with MNNG prior
the analysis (***p < 0.0005, **p < 0.001).
(G) Global ATP levels after 24 hr treatment with either media (black bar) or NR
(1 mM; dark gray bar), or NR (10 mM) followed by media alone or media
supplemented with MNNG (5 mM, 1 hr; dark-gray, light-gray and white bars;
*p < 0.05).
(H) OCR metabolic profile of LN428/MPG cells treated with either media
control or NR (1 mM) and/or FK866 (10 nM) followed by media alone or media
supplement with MNNG (5 mM, 1 hr). Data are the mean of four independent
experiments ± SD (***p < 0.005, **p < 0.01, *p < 0.05).
(I) ECAR profile of LN428/MPG cells treated with either media or media sup-
plementedwith 1mMNR for 24hr followedbya 1hr treatmentwithMNNG.Data
are the mean of three independent experiments ± SD (**p < 0.01, *p < 0.05).
1824 Cell Reports 8, 1819–1831, September 25, 2014 ª2014 The Aupolymers synthesized by ARTD1 hyperactivation, we stably
depleted PARG in LN428 cells (Figure S5A). As expected, the
absence of PARG elevates the steady-state level of PAR in
response to MNNG treatment (Figure S5B). The global NAD+
pool was depleted to a greater degree in LN428/PARG-KD cells
than in LN428 cells when exposed to increasing concentrations
of MNNG but the global ATP pool was not reduced (Figures 4A
and 4B). As predicted by the loss of NAD+ following MNNG treat-
ment, we observed a dose-dependent decrease of TRC in both
the LN428 and LN428/PARG-KD cell lines (Figures 4D and
S5C). In line with a role for PARG in the PAR-mediated ATP loss,
the oligomycin-induced ECAR is stable in the LN428/PARG-KD
cells but decreases in the LN428 cells (Figures 4C and S5D).
Together, these data suggest that loss of PARG (LN428/PARG-
KD cells) confers resistance to the glycolytic block induced by
ARTD1 activation and implicates PARG (via PAR hydrolysis) in
the crosstalk between the nucleus and the mitochondria.
PAR Interactome following MNNG-Induced
Accumulation of BER Intermediates
Because NAD+ biosynthesis inhibition is not sufficient to
decrease glycolysis and the block to glycolysis is impacted bythors
PARG expression, we hypothesized that ARTD1 activation and
the subsequent production of PAR might be causing the inhibi-
tion of glycolysis. We therefore sought to examine proteins that
interact with or are modified by PAR following induction by
MNNG treatment. We reasoned that the ‘‘PAR interactome’’
would provide insight into the relationship between ARTD1 acti-
vation and the loss of glycolysis. We used a specially designed
cell line in which Polß is disrupted by shRNA-mediated
knockdown and re-expressed with its catalytically dead form
(50deoxyribose phosphate, 50dRP, lyase Polß mutant K72A).
We reasoned that enhanced and persistent BER intermediates
and higher activation of ARTD1 in the isogenic cell line LN428/
MPG/Polß-KD/Flag-Polß(K72) at MNNG doses 20-fold lower
than that used in earlier proteome-wide analyses would provide
an ideal platform to identify PAR-modified and PAR-interacting
proteins resulting from MNNG exposure.
Exposure of LN428/MPG/Polß-KD/Flag-Polß(K72) cells to
MNNG (5 mM, 5 min) and isolation of PAR-containing complexes
through antibody-based affinity purification was done essentially
as described (Gagne´ et al., 2008, 2012; Figure S6A). Proteins
either covalently modified by PAR or those in amultiprotein com-
plex with PAR were identified by liquid-chromatography tandem
mass spectrometry (LC-MS/MS) to establish a PAR-interactome
in response toMNNG (Figure S6B and Files S1 and S2). Aswould
be expected, the majority of the proteins identified are DNA
repair and DNA damage response proteins, but we also found
many novel pathways that are significantly overrepresented,
including mitochondrial transport and organization, RNA biosyn-
thesis and transcription as well as chromatin assembly (Figures
S6B and S6C). Consistent with our findings that ARTD1-activa-
tion may have a direct role in altering energy metabolism, we
also found a significant number of proteins that reside in the
mitochondria and function to synthesize metabolic precursors
and energy metabolites (Figures S6B and S6C). These include
four proteins involved in glycolysis and ATP metabolism: HK1,
the mitochondrial channel proteins voltage-dependent anion
channels 1 and 2 (VDAC1 and 2) and the ATP/ADP translocase
2, ANT2 (see Files S1 and S2). For validation, an identical anti-
body-based affinity-purification workflow was followed by im-
munoblots for selected proteins to independently confirm the
covalently PARylated and PAR-bound protein complexes. Treat-
ment of LN428/MPG/Polß-KD/Flag-Polß(K72) cells yielded the
expected PAR-bound complexes including ARTD1, XRCC1,
DNA-PKcs, and H2B (Figure 5A), as well as DNA ligase III and
VDAC1 (Figure S6E). Consistent with the liquid chromatog-
raphy-tandem mass spectroscopy analysis, we find that some
of the validated proteins are ether bound to or modified by
PAR even in the absence of MNNG treatment.
Loss of Hexokinase 1 Subcellular Localization and
Activity due to DNA Damage-Induced ARTD1 Activation
The identification of the HK1/VDAC ATP biosynthesis network in
our PAR interactome (Figure S6F) presents a mechanistic link
between ARTD1 activation and DNA damage-induced block
to glycolysis, providing a direct confirmation of previous
bioinformatics analyses, which suggested that HK1 harbors a
PAR-binding motif (PBM) (Gagne´ et al., 2008). As a validation
of our proteomic screen, we found that an elevated level ofCell ReHK1 was in a complex with PAR upon MNNG treatment (Fig-
ure 5B). Reverse IP analysis was used to confirm whether HK1
is modified directly by PAR or is a PAR binding protein. EGFP-
tagged HK1 as well as EGFP-tagged XRCC1 or EGFP as a pos-
itive and negative control, respectively, were expressed in
LN428/MPG cells (Figure 5C). Whereas immunoprecipitation
(IP) of EGFP-tagged XRCC1 shows PAR covalent modification
(Figure 5C, last lane), neither EGFP nor EGFP-tagged HK1
show PAR modification after immunoblot (Figure 5C, first and
middle lanes), supporting the conclusion that the identity of
HK1 in our PAR-interactome is more likely the result of an
HK1/PAR complex forming via a PBM and not a covalent modi-
fication of HK1 by PAR.
The alignment of HK1 with bona fide PAR binding motifs from
histones H2A, H2B, H3, H4B (known to encode very strong
PBMs), XRCC1 (Pleschke et al., 2000), the mitochondrial protein
AIF (Wang et al., 2011; Yu et al., 2002, 2006), the stress signaling
protein DEK (Fahrer et al., 2010; Kappes et al., 2008), the exper-
imentally validated PBMwithin hnRNP-A1 (Gagne´ et al., 2003; Ji
et al., 2013; Ji and Tulin, 2009), and Werner syndrome protein
(Popp et al., 2013) supports that HK1 encodes aPBM (Figure 6A).
To confirm, we spotted purified BSA, histone H2B and HK1 (0.5,
1, and 2 mg) on a nitrocellulosemembrane and incubated in rena-
turating buffer containing in vitro synthesized PAR and analyzed
by a PAR immunoblot (Figure 6B). As a control experiment, the
spotted proteins were incubated in renaturating buffer without
PAR (Figure S6G). As expected, BSA does not bind PAR
whereas histone H2B presents a strong PAR-binding signal.
More importantly, we find that HK1 also binds PAR. However,
mutation of three essential amino residues within the HK1-
PBM to alanine (Figure 6A) reduces PAR binding to background
levels (Figure 6C). Furthermore, a far-western blot with these IP
extracts shows no additional PAR binding proteins, indicating
the PAR-binding signal in the slot-blot derives from an interac-
tion between PAR and HK1 (Figure S6H). We suggest from these
studies that the interaction between HK1 and PAR is not a cova-
lent interaction and that HK1 encodes a PBM that when mutated
no longer binds PAR.
We hypothesized that ARTD1 activation and the release of
PAR by PARG may alter ATP biosynthesis through PAR binding
to HK1. HK1 catalyzes the first step of glycolysis by phosphory-
lating glucose and generating glucose-6-phosphate. HK1 inter-
acts with the outer mitochondrial membrane protein VDAC and
the disruption of its interaction leads to a decrease in the rate
of glycolysis (Shoshan-Barmatz and Golan, 2012), presumably
due to either an allosteric effect or a decrease in the availability
of VDAC transported ATP. To depict HK1 subcellular localiza-
tion, we expressed HK1 in the LN428/MPG cells as a fusion
with EGFP. Under normal conditions, HK1 is localized on the
mitochondria and colocalized with the mitochondrial protein
Tom20 (Figures 6D and S6I). However, after MNNG treatment,
localization of HK1 is also cytoplasmic (Figure 6D). In a parallel
evaluation, we characterized the localization of HK1 by a
biochemical analysis. In untreated cells, very little HK1 is local-
ized to the cytosol (Figure 6E). However, MNNG treatment
induces a significant increase in cytosolic HK1 relocalization
(Figure 6E, upper) with little to no observed cytosolic HK1
relocalization in LN428 cells (Figure 6E, lower; Figure S1D).ports 8, 1819–1831, September 25, 2014 ª2014 The Authors 1825
Figure 5. Affinity-Purification and Analysis of PAR-Containing Complexes
(A) Validation by IP/immunoblot of DNA-PKcs, ARTD1, XRCC1, and H2B identified in the mass spectrometry analysis. Left: IP with the anti-PAR Ab 10H and
immunoblot with the indicated antibodies. Right: immunoblot for PAR after IP with the anti-PAR (10H) Ab.
(B) Validation by IP/immunoblot of HK1 enzyme identified in the mass spectrometry analysis as described in (A).
(C) Upper: the GFP immunoblot on inputs and IP samples after pull-down of GFP-tagged proteins with GFP-Trap. Cells are treated either with the ARTD1 inhibitor
ABT-888 (10 mM; 30 min) or with MNNG (5 mM; 5 min). Lower: PAR immunoblot on inputs and IP samples. PAR immunoblot on IP samples is shown as short and
long exposures.Furthermore, we observed that the MNNG-induced cytosolic
HK1 relocalization is suppressed by pretreatment with the
ARTD1 inhibitor ABT-888 or bymutation of the HK1 PAR-binding
motif, HK1/PBM (Figure S6J). Moreover, HK1 activity was found
to be 3-fold lower in LN428/MPGcells treatedwithMNNG than in
untreated cells and HK1 activity was restored by ARTD1 inhibi-
tion or knockdown (Figure 6F), indicating a role of ARTD1 hyper-
activation in HK1 inactivation. It is noteworthy that even a 3-fold
higher dose of MNNG does not lead to HK1 activity alteration in
LN428/ARTD1-KD/MPG cells (Figure 6F). Interestingly, MNNG
treatment of LN428 cells leads to a slight HK1 activity decrease
yet not to the same extent as in LN428/MPG cells (Figure 6G, up-
per) and the knockdown of PARG partially rescues these defects
(Figure 6G, lower). Furthermore, we measured HK1 activity after
incubation of purified HK1 with 50 or 100 pmol of in vitro synthe-
sized PAR (Figure 6H) and observed a progressive decrease in
HK1 activity with increasing doses of PAR, demonstrating a
direct role of ARTD1 in HK1 inactivation.1826 Cell Reports 8, 1819–1831, September 25, 2014 ª2014 The AuTogether, these results support our hypothesis that HK1 is
a direct target of ARTD1 activation. Once activated, ARTD1-
induced PAR is released from the nucleus via PARG activity. In
turn, the DNA damage-induced loss of ATP biosynthesis can
be mediated by release of HK1 from the mitochondrial mem-
brane into the cytosol and PAR-mediated inhibition of HK1 activ-
ity. In total, the result is a block to glycolysis.
DISCUSSION
While cell death induced by ARTD1 hyperactivation is well docu-
mented, the precise mechanism underlying this observed
phenotype remains unresolved and is still a matter of debate.
In this study, we demonstrate that ARTD1-induced NAD+ deple-
tion is not the only factor to mediate metabolic collapse and
induce cell death. On the contrary, we show an unambiguous,
direct role of ARTD1, through the induction of PAR and the
inhibition of hexokinase 1 activity, clarifying the mechanism ofthors
ARTD1-directedmetabolic collapse. Most importantly, our study
brings insight into the importance of the crosstalk between nu-
clear ARTD1 activity and other cell compartments, particularly
the mitochondria (Andrabi et al., 2008).
It is well established that PAR produced after DNA damage is a
key intermediate that triggers a cascade of events leading to cell
death. One of these events, initially postulated ‘‘PARP-assisted
cell suicide,’’ attempts to explain the observed cell death by
speculating that NAD+ depletion caused by ARTD1 hyperactivity
causes a shut-down of NAD+/NADH-dependent metabolic path-
ways followed by ATP depletion and the onset of necrosis
(Berger et al., 1983; Ha and Snyder, 1999; Vyas et al., 2013). In
line with this theory, we report a significant energy defect in
DNA damaged cells due to ARTD1 hyperactivation. We have
used two state-of-the-art techniques in live cells to show that
incomplete repair of MNNG-induced DNA damage causes a
massive increase in ARTD1 activity and a subsequent decline
in ATP supplied from both oxidative phosphorylation and glycol-
ysis. Whereas others have reported a decrease of the mitochon-
drial membrane potential (Juarez-Salinas et al., 1979; Leung
et al., 2012), we have been able to measure a loss of total mito-
chondrial reserve capacity (TRC), a mitochondrial defect, which
evaded detection in past studies using mitochondrial extracts.
Glycolysis and the TCA cycle are the two main NAD+-
consumingpathways in cells aswell as themajorNADHproviders
to the respiratory chain that produce ATP. Although the shutdown
of these pathways by ARTD1 hyperactivation-mediated NAD+
loss could explain the respiratory defects in cells exposed to
DNAdamage, lossofNAD+productionbydirect enzymatic inhibi-
tion of NAMPT using FK866 did not cause a decrease in glycol-
ysis. Because these data are in contrast to current models (Alano
et al., 2010), we demonstrate that the glycolytic block upon
MNNG treatment is not a mere consequence of NAD+ loss.
Rather, we speculate that ARTD1 hyperactivation has a direct ef-
fect on glycolysis via PAR. This hypothesis is further supportedby
the lack of a glycolysis rate rescue after NAD+ synthesis precursor
pretreatment,whereasARTD1 inhibitionbyABT-888orBMN-673
as well as ARTD1 knockdown, restores glycolysis.
Consistent with our hypothesis that ARTD1 directly affects
glycolysis, we identified the glycolytic protein HK1, the enzyme
responsible for the first step of glycolysis, as a potential PAR
binding protein by mass spectrometry. We find that although
HK1 is not covalently modified by ARTD1, HK1 binds PAR
through a PBM earlier identified by mass spectrometry analysis
(Gagne´ et al., 2008). HK1 is one of the three major isoenzymes of
the hexokinase family. HK1 is mainly associated with the outer
mitochondrial membrane through an interaction with the channel
protein VDAC, also identified in our PAR binding protein mass
spectrometry analysis (see Files S1 and S2; Jun et al., 2012; Wil-
son, 2003). This physical interaction couples cytosolic glycolysis
to mitochondrial oxidative phosphorylation by which the cells
produce most of their ATP and potentially links ARTD1 activity
and PAR to the metabolic events in the mitochondria. Indeed,
a previous study has demonstrated that during ischemic
renal injury, ARTD1 can poly(ADP-ribosyl)ate and inhibit glycer-
aldehyde-3-phosphate-dehydrogenase (GAPDH), the enzyme
responsible for the catalysis of the second step of glycolysis
(Devalaraja-Narashimha and Padanilam, 2009). We alsoCell Reobserved that GAPDH is bound or modified by PAR but at an
extremely low level, suggesting that the PAR-interactome we
have identified may be selective for a cellular response to BER
intermediates (see Files S1 and S2). Our PAR binding protein
mass spectrometry analysis also identified three enzymes
involved in the Krebs cycle (succinate dehydrogenase, alpha-
ketoglutarate dehydrogenase, and pyruvate dehydrogenase),
suggesting a possible role of ARTD1 in the regulation of these
enzyme activities after DNA damage. Consistent with this idea,
we found that although NR pretreatment is able to partly rescue
the global NAD+ pool after MNNG treatment at low doses, both
the TRC and ECAR were still affected (Figures S4G and S4H).
Ying and colleagues previously demonstrated that treatment of
murine astrocytes after MNNG with TCA cycle intermediates
partly rescued cell death (Ying et al., 2002). These results confirm
our observation that ARTD1 hyperactivation is directly involved
in the inhibition of glycolysis after MNNG treatment and does
not exclude the possible involvement of ARTD1 in the control
of the TCA cycle enzymes.
MNNG-induced ARTD1 hyperactivation could negatively
affect glycolysis by creating excess PAR able to migrate into
the cytosol and bind to HK1 and thus inhibit its enzyme activity.
In support of this hypothesis, we find that the ECAR values of
LN428/PARG-KD cells are more resistant to MNNG than
LN428 cells. In addition, we observe a decrease in HK1 activity
in LN428/MPG cell lysates after MNNG treatment that is rescued
by ARTD1 inhibition, and more importantly a direct effect of HK1
activity upon in vitro incubation with PAR. These two key results
constitute strong evidence for a role of ARTD1 in controlling HK1
activity under cellular stress. Interestingly, some studies corre-
late HK1 subcellular localization and activity. It has been demon-
strated that the release of HK1 can affect its activity (Saraiva
et al., 2010). HK1 release from the mitochondria may also be
responsible for a decrease in the mitochondrial membrane
potential and can promote tumor necrosis factor-induced
apoptosis in HeLa cells (Ullu et al., 2002). Intriguingly, we find a
mobilization of HK1 from the mitochondria to the cytosol after
MNNG treatment in LN428/MPG cells, consistent with the
observed reduction of HK1 activity.
These findings suggest a working model in which ARTD1 hy-
peractivation leads to inhibition of HK1 and mislocalization of
HK1 from the outer mitochondrial membrane, leading to a reduc-
tion in cellular glycolysis and depletion in cellular ATP pools. This
effect of ARTD1 activity coupled with NAD+ depletion might
explain the cell sensitivity in response to DNA alkylation damage
and the resulting ARTD1 activation that is induced due to unre-
paired DNA strand breaks and BER intermediates. PAR could
affect HK1 activity in two nonmutually exclusive ways. First,
PAR binding to HK1 could cause a decrease in its affinity to
VDAC causing its migration into the cytoplasm. Second, PAR
binding could allosterically affect HK1 activity. Data presented
here support both mechanisms. Furthermore, high-resolution
crystal structures indicate that the putative PBM of HK1 is
located in an accessible surface area that overlaps with a helix
in its N-terminal domain (Rosano, 2011). This helical domain is
involved both in the binding of ATP and in the interaction of
HK1 with the mitochondrial protein channel VDAC1, making
both scenarios plausible.ports 8, 1819–1831, September 25, 2014 ª2014 The Authors 1827
Figure 6. MNNG-Mediated ARTD1 Activation Leads to Hexokinase 1 Release from the Mitochondria and Loss of Activity
(A) Alignment of the PAR Binding domains (PBM) of histone H2A, H2B, H3, H4, DEK, AIF, WRN, XRCC1, HNRNPA1, and HK1 with the consensus PBM identified
previously (Gagne´ et al., 2008; Pleschke et al., 2000). *Indicates the amino acids in the putative PBM of HK1 mutated to alanine, A.
(B) PAR dot blot performed with 0.5, 1, or 2 mg BSA, histone H2B or HK1, as indicated. Shown is one experiment among four performed independently.
(C) PAR overlay performed by slot blot. Each protein was expressed in LN428 cells as a fusion with EGFP and isolated using GFP-Trap. The isolated proteins were
bound to the membrane and incubated either with a GFP antibody (left) or PAR (right) followed by incubation with the anti-PAR (10H) antibody.
(D) Immunodetection by immunofluorescence of EGFP-tagged HK1 in LN428/MPG cells treated for 1 hr with media or MNNG (5 mM).
(E) HK1 is released from the mitochondria, into the cytoplasm, after MNNG treatment. Immunoblot of endogenous HK1 in LN428/MPG cytosolic extracts (upper).
Lower: Cytosolic extracts of LN428 cells performed after 1 hr treatment with 0, 5, or 10 mMMNNG. Actin is shown as a loading control and Tom20 as a control to
demonstrate the absence of mitochondrial proteins.
(F and G) Specific HK1-acitivity measurement in LN428/MPG (plain bars) and LN428/ARTD1-KD/MPG cells (hatched bars) (F) or LN428 (upper) and LN428/
PARG-KD cells (lower) (G) LN428/MPG cells are pretreated (1 hr) with either media (black bar) or PJ34 (2 mM; light-gray bar) prior to MNNG treatment (dark-gray
and white bars). Shown is the mean of three independent experiments ± SD (**p < 0.005, *p < 0.05). LN428/ARTD1-KD/MPG cells are treated (1 hr) with MNNG
(legend continued on next page)
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Another group reported that mouse cortical neurons treated
with high-dose MNNG undergo ARTD1-dependent energy
depletion that is mediated by glycolysis inhibition (Andrabi
et al., 2014). The authors hypothesize that PAR-induced release
of AIF could be responsible for the ARTD1 activation-induced
decrease in HK1 activity via the loss of an interaction between
both proteins. Further to this point, we demonstrate the ARTD1
activation-dependent release of HK1 into the cytosol, previously
suggested as being responsible for HK1 inhibition (Saraiva et al.,
2010). In addition to demonstrating the PAR-dependent release
of HK1, we also show that the HK1-PBM is required for ARTD1
activation-induced inhibition of HK1, implicating binding of
PAR to HK1 as a requisite event. Future studies will reveal the
role of PAR in the regulation of HK1 and the contribution of this
interaction to the loss of glycolysis, mitochondrial dysfunction,
and the onset of parthanatos in response to genotoxin exposure.
In summary, we propose amodel in which DNA repair interme-
diates induce ARTD1 hyperactivation. In turn, the resulting PAR
synthesis leads to a release of PAR units in the cytoplasm, which
upon binding to HK1 causes the decrease of its activity and/or its
dissociation from VDAC, leading to its release into the cytoplasm
and a subsequent decrease in its activity. Such amodel, in which
PAR would be required to migrate from the nucleus to the mito-
chondria, is consistent with a role for both PARG and the ADP-
ribosylhydrolase like 2 protein (ARH3) regulating such a
response, as recently suggested (Mashimo et al., 2013). Data
presented in this study therefore provide amolecular mechanism
linking DNA damage induced ARTD1 hyperactivation to cell
death through the direct inhibition of glycolysis by diminishing
HK1 activity. These data are in contrast to the previously pro-
posed ‘‘secondary shutdown’’ of the glycolytic pathway by
ARTD1-mediated NAD+ depletion. Our findings have wide-
ranging implications not only for the fields of DNA repair, BER,
and chemotherapy, but also for diseases in which ARTD1 activa-
tion plays a prominent role, such as ischemic injury after stroke
or myocardial infarction, traumatic brain injury, Parkinson dis-
ease, and septic shock.EXPERIMENTAL PROCEDURES
More details on the experimental procedures are provided in the Supplemental
Experimental Procedures section.
Cell Culture
The cell line LN428 has been established as previously reported and LN428/
MPG cells were prepared and cultured as described (Tang et al., 2010).
LN428/ARTD1-KD/copGFP, LN428/ARTD1-KD/MPG-copGFP, LN428/MPG/
PARG-KD, and LN428/PARG-KD cells are stable cell lines developed by
lentiviral transduction, essentially as described (Goellner et al., 2011; Svilar
et al., 2012; Tang et al., 2010).
Cell Cytotoxicity
MNNG- and FK866-induced cytotoxicity was determined by an MTS assay
and a modified MTT assay as described previously (Tang et al., 2010).(5 mM, hatched light-gray bar and 15 mM, hatched dark-gray bar). ns, nonsignific
treated LN428/MPG cells. LN428 and LN428/PARG-KD cells were treated with 5
(H) PAR binding leads to HK1 activity decrease in vitro. HK1 activity is measured
(50 pmol or 100 pmol), using an HK1 colorimetric assay. Data are the mean of tw
Cell ReHexokinase Activity
Hexokinase activity of purified protein and from cell lysates was measured
using the Hexokinase Colorimetric Assay (BioVision).
Global NAD+ and ATP Measurements
Global NAD+ and ATP pools were measured using the EnzyChrom NAD+/
NADH Assay kit (BioAssay Systems) and the ATP lite assay kit (Perkin-Elmer),
respectively.
Subcellular ATP Analysis
Subcellular ATP levels were evaluated by fluorescence resonance energy
transfer (FRET) using the ATeam probes composed of mVenus and mseCFP
linked to the ε subunit of Bacillus subtilis F0F1-ATP synthase (Imamura et al.,
2009a) and targeted to the three different cell compartments.
Metabolic Flux Measurement
The OCRs and ECARs were measured using the Seahorse Extracellular Flux
Analyzer (Seahorse Bioscience), essentially as described (Furda et al., 2012;
Qian and Van Houten, 2010; Varum et al., 2011).
PAR Dot Blot and Far Western Blot
PAR was synthesized in vitro as previously described (Ame´ et al., 2009) or ob-
tained in purified form from Trevigen (#4336-100-01). Purified proteins (BSA,
H2B or HK1; 0.5, 1 or 2 mg) were spotted on a nitrocellulose membrane and
incubated in renaturing buffer containing PAR polymers. The presence of
bound PAR was then detected by immunoblot using the 10H anti-PAR anti-
body. For the far western blot, GFP-tagged proteins were expressed in
LN428 cells, isolated using GFP-Trap (Chromotek) beads, and resolved by
SDS-PAGE followed by transfer to a nitrocellulose membrane. The membrane
was incubated in renaturing buffer as described above and the PAR signal was
detected using 10H antibody conjugated to biotin, followed by incubation with
streptavidin-HRP.
Immunoprecipitation
LN428/MPG/Polß-KD/FLAG-Polß(K72A) or LN428/MPG cells were seeded
onto 15 mm dishes and grown to 80%–90% confluence. Cells were either
treated with ABT-888 (10 mM, 1 hr) and/or with MNNG (5 mM, 5 min) and
then cell lysates were prepared for immunoprecipitation with either the 10H
anti-PAR Ab or the GFP-Trap (Chromotek).
Immunofluorescence and Confocal Microscopy
Cells were seeded on glass coverslips for 24 hr beforeMNNG treatment during
the time indicated preceded by PJ34 (or vehicle) pretreatment. The immuno-
detection of PAR was performed as previously described (Ame´ et al., 2009).
For immunodetection of HK1-GFP, cells were modified to express HK1-GFP
by transfection with pEGFP-N3-FLHK1 (AddGene) using the transfection re-
agent JetPrime (VWR) 24 hr prior to the cell treatment and fixation for immuno-
fluoresence. To depict the mitochondria, an antibody against the membrane
protein Tom20 has been used (SantaCruz).
Mass Spectrometry
After immunoprecipitation of the PAR binding complexes, mass spectrometry
analyses were performed on a TripleTOF 5600mass spectrometer fitted with a
nanospray III ion source (ABSciex) and coupled to an Agilent 1200 HPLC
(extensive details are reported in the Supplemental Experimental Procedures).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, Excel and Scaffold database files, and three movies and can be
foundwith this article online at http://dx.doi.org/10.1016/j.celrep.2014.08.036.ant compared to LN428/MPG cells untreated; *p < 0.05 compared to MNNG
mM, 10 mM, and 20 mM MNNG (1 hr).
in vitro 20 min after incubation of 0.25 mg of HK1 with in vitro synthesized PAR
o independent experiments ± SD.
ports 8, 1819–1831, September 25, 2014 ª2014 The Authors 1829
AUTHOR CONTRIBUTIONS
E.F., E.G., J.P.G., G.G.P., and R.W.S. designed the experiments; E.F., E.G.,
Z.Y., and J.P.G. performed the experiments; E.F., E.G., J.P.G., G.G.P.,
D.W., M.M., G.R., and R.W.S. analyzed data; P.R., J.L., T.F., M.B.M., and
M.M. contributed new reagents/analytic tools; E.F., E.G., and R.W.S. wrote
the paper with comments by Z.Y., D.W., P.R., G.R., J.P.G., G.G.P., M.M.,
and B.V.H.
ACKNOWLEDGMENTS
This work was supported by grants from NIH (CA148629, GM087798,
ES019498, ES021116, GM099213, and CA148629-04S1) to R.W.S., from the
Canadian Institutes of Health Research (MOP-178013, MOP-209278) to
G.G.P., and from PA CURE to B.V.H. Support for the synthetic chemistry con-
ducted by P.R. was provided by the John King Laboratory Funds. Support was
also provided by the University of Pittsburgh Department of Pharmacology &
Chemical Biology through a Pharmacology Fellowship to E.M.G. G.G.P. holds
a Tier1 Canada Chair in Proteomics. B.V.H. holds the Richard M. Cyert Chair
as Professor of Molecular Oncology. Support for the UPCI Lentiviral (Vector
Core) Facility and the UPCI Cell and Tissue Imaging Facility was provided in
part by the Cancer Center Support Grant from the NIH (P30CA047904).
RWS is a scientific consultant for Trevigen, Inc.
Received: February 18, 2014
Revised: August 11, 2014
Accepted: August 19, 2014
Published: September 11, 2014
REFERENCES
Alano, C.C., Ying, W., and Swanson, R.A. (2004). Poly(ADP-ribose) polymer-
ase-1-mediated cell death in astrocytes requires NAD+ depletion and mito-
chondrial permeability transition. J. Biol. Chem. 279, 18895–18902.
Alano, C.C., Garnier, P., Ying, W., Higashi, Y., Kauppinen, T.M., and Swanson,
R.A. (2010). NAD+ depletion is necessary and sufficient for poly(ADP-ribose)
polymerase-1-mediated neuronal death. J. Neurosci. 30, 2967–2978.
Almeida, K.H., and Sobol, R.W. (2007). A unified view of base excision repair:
lesion-dependent protein complexes regulated by post-translational modifica-
tion. DNA Repair (Amst.) 6, 695–711.
Ame´, J.C., Hakme´, A., Quenet, D., Fouquerel, E., Dantzer, F., and Schreiber, V.
(2009). Detection of the nuclear poly(ADP-ribose)-metabolizing enzymes and
activities in response to DNA damage. Methods Mol. Biol. 464, 267–283.
Andrabi, S.A., Kim, N.S., Yu, S.W., Wang, H., Koh, D.W., Sasaki, M., Klaus,
J.A., Otsuka, T., Zhang, Z., Koehler, R.C., et al. (2006). Poly(ADP-ribose)
(PAR) polymer is a death signal. Proc. Natl. Acad. Sci. USA 103, 18308–18313.
Andrabi, S.A., Dawson, T.M., and Dawson, V.L. (2008). Mitochondrial and nu-
clear cross talk in cell death: parthanatos. Ann. N Y Acad. Sci. 1147, 233–241.
Andrabi, S.A., Umanah, G.K., Chang, C., Stevens, D.A., Karuppagounder,
S.S., Gagne´, J.P., Poirier, G.G., Dawson, V.L., and Dawson, T.M. (2014).
Poly(ADP-ribose) polymerase-dependent energy depletion occurs through
inhibition of glycolysis. Proc. Natl. Acad. Sci. USA 111, 10209–10214.
Berger, N.A. (1985). Poly(ADP-ribose) in the cellular response to DNA damage.
Radiat. Res. 101, 4–15.
Berger, N.A., Sims, J.L., Catino, D.M., and Berger, S.J. (1983). Poly(ADP-
ribose) polymerase mediates the suicide response to massive DNA damage:
studies in normal and DNA-repair defective cells. Int. Symp. Princess Taka-
matsu Cancer Res. Fund 13, 219–226.
Burns, N., and Gold, B. (2007). The effect of 3-methyladenine DNA glycosy-
lase-mediated DNA repair on the induction of toxicity and diabetes by the
beta-cell toxicant streptozotocin. Toxicol. Sci. 95, 391–400.
Calvo, J.A., Moroski-Erkul, C.A., Lake, A., Eichinger, L.W., Shah, D., Jhun, I.,
Limsirichai, P., Bronson, R.T., Christiani, D.C., Meira, L.B., and Samson,
L.D. (2013). Aag DNA glycosylase promotes alkylation-induced tissue damage
mediated by Parp1. PLoS Genet. 9, e1003413.1830 Cell Reports 8, 1819–1831, September 25, 2014 ª2014 The AuCipriani, G., Rapizzi, E., Vannacci, A., Rizzuto, R., Moroni, F., and Chiarugi, A.
(2005). Nuclear poly(ADP-ribose) polymerase-1 rapidly triggers mitochondrial
dysfunction. J. Biol. Chem. 280, 17227–17234.
De Vos, M., Schreiber, V., and Dantzer, F. (2012). The diverse roles and clinical
relevance of PARPs in DNA damage repair: current state of the art. Biochem.
Pharmacol. 84, 137–146.
Devalaraja-Narashimha, K., and Padanilam, B.J. (2009). PARP-1 inhibits
glycolysis in ischemic kidneys. J. Am. Soc. Nephrol. 20, 95–103.
Eliasson, M.J., Sampei, K., Mandir, A.S., Hurn, P.D., Traystman, R.J., Bao, J.,
Pieper, A., Wang, Z.Q., Dawson, T.M., Snyder, S.H., and Dawson, V.L. (1997).
Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cere-
bral ischemia. Nat. Med. 3, 1089–1095.
Endres, M., Wang, Z.Q., Namura, S., Waeber, C., and Moskowitz, M.A. (1997).
Ischemic brain injury is mediated by the activation of poly(ADP-ribose)poly-
merase. J. Cereb. Blood Flow Metab. 17, 1143–1151.
Fahrer, J., Popp, O., Malanga, M., Beneke, S., Markovitz, D.M., Ferrando-May,
E., Bu¨rkle, A., and Kappes, F. (2010). High-affinity interaction of poly(ADP-
ribose) and the human DEK oncoprotein depends upon chain length.
Biochemistry 49, 7119–7130.
Fu, D., Calvo, J.A., and Samson, L.D. (2012). Balancing repair and tolerance of
DNA damage caused by alkylating agents. Nat. Rev. Cancer 12, 104–120.
Furda, A.M., Marrangoni, A.M., Lokshin, A., and Van Houten, B. (2012). Oxi-
dants and not alkylating agents induce rapid mtDNA loss and mitochondrial
dysfunction. DNA Repair (Amst.) 11, 684–692.
Gagne´, J.P., Hunter, J.M., Labrecque, B., Chabot, B., and Poirier, G.G. (2003).
A proteomic approach to the identification of heterogeneous nuclear ribonu-
cleoproteins as a new family of poly(ADP-ribose)-binding proteins. Biochem.
J. 371, 331–340.
Gagne´, J.P., Isabelle, M., Lo, K.S., Bourassa, S., Hendzel, M.J., Dawson, V.L.,
Dawson, T.M., and Poirier, G.G. (2008). Proteome-wide identification of
poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein
complexes. Nucleic Acids Res. 36, 6959–6976.
Gagne´, J.P., Pic, E., Isabelle, M., Krietsch, J., Ethier, C., Paquet, E., Kelly, I.,
Boutin, M., Moon, K.M., Foster, L.J., and Poirier, G.G. (2012). Quantitative pro-
teomics profiling of the poly(ADP-ribose)-related response to genotoxic
stress. Nucleic Acids Res. 40, 7788–7805.
Goellner, E.M., Grimme, B., Brown, A.R., Lin, Y.C., Wang, X.H., Sugrue, K.F.,
Mitchell, L., Trivedi, R.N., Tang, J.B., and Sobol, R.W. (2011). Overcoming
temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosyn-
thesis and base excision repair. Cancer Res. 71, 2308–2317.
Gottipati, P., Vischioni, B., Schultz, N., Solomons, J., Bryant, H.E., Djureinovic,
T., Issaeva, N., Sleeth, K., Sharma, R.A., and Helleday, T. (2010). Poly(ADP-
ribose) polymerase is hyperactivated in homologous recombination-defective
cells. Cancer Res. 70, 5389–5398.
Ha, H.C., and Snyder, S.H. (1999). Poly(ADP-ribose) polymerase is a mediator
of necrotic cell death by ATP depletion. Proc. Natl. Acad. Sci. USA 96, 13978–
13982.
Hasmann,M., and Schemainda, I. (2003). FK866, a highly specific noncompet-
itive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel
mechanism for induction of tumor cell apoptosis. Cancer Res. 63, 7436–7442.
Hassa, P.O., Haenni, S.S., Elser, M., and Hottiger, M.O. (2006). Nuclear ADP-
ribosylation reactions in mammalian cells: where are we today and where are
we going? Microbiol. Mol. Biol. Rev. 70, 789–829.
Hottiger, M.O., Hassa, P.O., Lu¨scher, B., Schu¨ler, H., and Koch-Nolte, F.
(2010). Toward a unified nomenclature for mammalian ADP-ribosyltrans-
ferases. Trends Biochem. Sci. 35, 208–219.
Imamura, H., Nhat, K.P., Togawa, H., Saito, K., Iino, R., Kato-Yamada, Y.,
Nagai, T., and Noji, H. (2009b). Visualization of ATP levels inside single living
cells with fluorescence resonance energy transfer-based genetically encoded
indicators. Proc. Natl. Acad. Sci. USA 106, 15651–15656.
Jacobson, M.K., Levi, V., Juarez-Salinas, H., Barton, R.A., and Jacobson, E.L.
(1980). Effect of carcinogenic N-alkyl-N-nitroso compounds on nicotinamide
adenine dinucleotide metabolism. Cancer Res. 40, 1797–1802.thors
Ji, Y., and Tulin, A.V. (2009). Poly(ADP-ribosyl)ation of heterogeneous nuclear
ribonucleoproteins modulates splicing. Nucleic Acids Res. 37, 3501–3513.
Ji, Y., Jarnik, M., and Tulin, A.V. (2013). Poly(ADP-ribose) glycohydrolase and
poly(ADP-ribose)-interacting protein Hrp38 regulate pattern formation during
Drosophila eye development. Gene 526, 187–194.
Juarez-Salinas, H., Sims, J.L., and Jacobson, M.K. (1979). Poly(ADP-ribose)
levels in carcinogen-treated cells. Nature 282, 740–741.
Jun, B.H., Kang, H., Lee, Y.S., and Jeong, D.H. (2012). Fluorescence-based
multiplex protein detection using optically encoded microbeads. Molecules
17, 2474–2490.
Kappes, F., Fahrer, J., Khodadoust, M.S., Tabbert, A., Strasser, C., Mor-
Vaknin, N., Moreno-Villanueva, M., Bu¨rkle, A., Markovitz, D.M., and
Ferrando-May, E. (2008). DEK is a poly(ADP-ribose) acceptor in apoptosis
and mediates resistance to genotoxic stress. Mol. Cell. Biol. 28, 3245–3257.
Langelier, M.F., Planck, J.L., Roy, S., and Pascal, J.M. (2012). Structural basis
for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Sci-
ence 336, 728–732.
Leung, A., Todorova, T., Ando, Y., and Chang, P. (2012). Poly(ADP-ribose)
regulates post-transcriptional gene regulation in the cytoplasm. RNA Biol. 9,
542–548.
Mashimo, M., Kato, J., and Moss, J. (2013). ADP-ribosyl-acceptor hydrolase 3
regulates poly (ADP-ribose) degradation and cell death during oxidative stress.
Proc. Natl. Acad. Sci. USA 110, 18964–18969.
Masson, M., Niedergang, C., Schreiber, V., Muller, S., Menissier-de Murcia, J.,
and de Murcia, G. (1998). XRCC1 is specifically associated with poly(ADP-
ribose) polymerase and negatively regulates its activity following DNA dam-
age. Mol. Cell. Biol. 18, 3563–3571.
Masutani, M., Suzuki, H., Kamada, N., Watanabe, M., Ueda, O., Nozaki, T.,
Jishage, K., Watanabe, T., Sugimoto, T., Nakagama, H., et al. (1999).
Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to
streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. USA 96, 2301–2304.
Pieper, A.A., Brat, D.J., Krug, D.K., Watkins, C.C., Gupta, A., Blackshaw, S.,
Verma, A., Wang, Z.Q., and Snyder, S.H. (1999). Poly(ADP-ribose) polymer-
ase-deficient mice are protected from streptozotocin-induced diabetes.
Proc. Natl. Acad. Sci. USA 96, 3059–3064.
Pieper, A.A., Walles, T., Wei, G., Clements, E.E., Verma, A., Snyder, S.H.,
and Zweier, J.L. (2000). Myocardial postischemic injury is reduced by
polyADPripose polymerase-1 gene disruption. Mol. Med. 6, 271–282.
Pleschke, J.M., Kleczkowska, H.E., Strohm, M., and Althaus, F.R. (2000).
Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint pro-
teins. J. Biol. Chem. 275, 40974–40980.
Popp, O., Veith, S., Fahrer, J., Bohr, V.A., Bu¨rkle, A., and Mangerich, A. (2013).
Site-specific noncovalent interaction of the biopolymer poly(ADP-ribose) with
the Werner syndrome protein regulates protein functions. ACS Chem. Biol. 8,
179–188.
Qian, W., and Van Houten, B. (2010). Alterations in bioenergetics due to
changes in mitochondrial DNA copy number. Methods 51, 452–457.
Rosano, C. (2011). Molecular model of hexokinase binding to the outer mito-
chondrial membrane porin (VDAC1): Implication for the design of new cancer
therapies. Mitochondrion 11, 513–519.Cell ReSaraiva, L.M., Seixas da Silva, G.S., Galina, A., da-Silva,W.S., Klein, W.L., Fer-
reira, S.T., and De Felice, F.G. (2010). Amyloid-b triggers the release of
neuronal hexokinase 1 from mitochondria. PLoS ONE 5, e15230.
Schreiber, V., Dantzer, F., Ame, J.C., and de Murcia, G. (2006). Poly(ADP-
ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 7,
517–528.
Shoshan-Barmatz, V., and Golan, M. (2012). Mitochondrial VDAC1: function
in cell life and death and a target for cancer therapy. Curr. Med. Chem. 19,
714–735.
Svilar, D., Goellner, E.M., Almeida, K.H., and Sobol, R.W. (2011). Base excision
repair and lesion-dependent subpathways for repair of oxidative DNA dam-
age. Antioxid. Redox Signal. 14, 2491–2507.
Svilar, D., Dyavaiah, M., Brown, A.R., Tang, J.B., Li, J., McDonald, P.R., Shun,
T.Y., Braganza, A., Wang, X.H., Maniar, S., et al. (2012). Alkylation sensitivity
screens reveal a conserved cross-species functionome. Mol. Cancer Res.
10, 1580–1596.
Tang, J.B., Goellner, E.M., Wang, X.H., Trivedi, R.N., St Croix, C.M., Jelez-
cova, E., Svilar, D., Brown, A.R., and Sobol, R.W. (2010). Bioenergetic metab-
olites regulate base excision repair-dependent cell death in response to DNA
damage. Mol. Cancer Res. 8, 67–79.
Ullu, E., Djikeng, A., Shi, H., and Tschudi, C. (2002). RNA interference: ad-
vances and questions. Philos. Trans. R. Soc. Lond. B Biol. Sci. 357, 65–70.
Varum, S., Rodrigues, A.S., Moura, M.B., Momcilovic, O., Easley, C.A., 4th,
Ramalho-Santos, J., Van Houten, B., and Schatten, G. (2011). Energy meta-
bolism in human pluripotent stem cells and their differentiated counterparts.
PLoS ONE 6, e20914.
Vyas, S., Chesarone-Cataldo, M., Todorova, T., Huang, Y.H., and Chang, P.
(2013). A systematic analysis of the PARP protein family identifies new func-
tions critical for cell physiology. Nat. Commun. 4, 2240.
Wang, Y., Kim, N.S., Haince, J.F., Kang, H.C., David, K.K., Andrabi, S.A., Poi-
rier, G.G., Dawson, V.L., and Dawson, T.M. (2011). Poly(ADP-ribose) (PAR)
binding to apoptosis-inducing factor is critical for PAR polymerase-1-depen-
dent cell death (parthanatos). Sci. Signal. 4, ra20.
Wilson, J.E. (2003). Isozymes of mammalian hexokinase: structure, subcellular
localization and metabolic function. J. Exp. Biol. 206, 2049–2057.
Ying, W., Chen, Y., Alano, C.C., and Swanson, R.A. (2002). Tricarboxylic acid
cycle substrates prevent PARP-mediated death of neurons and astrocytes.
J. Cereb. Blood Flow Metab. 22, 774–779.
Ying, W., Garnier, P., and Swanson, R.A. (2003). NAD+ repletion prevents
PARP-1-induced glycolytic blockade and cell death in cultured mouse astro-
cytes. Biochem. Biophys. Res. Commun. 308, 809–813.
Yu, S.W., Wang, H., Poitras, M.F., Coombs, C., Bowers, W.J., Federoff, H.J.,
Poirier, G.G., Dawson, T.M., and Dawson, V.L. (2002). Mediation of poly(ADP-
ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Sci-
ence 297, 259–263.
Yu, S.W., Andrabi, S.A., Wang, H., Kim, N.S., Poirier, G.G., Dawson, T.M., and
Dawson, V.L. (2006). Apoptosis-inducing factor mediates poly(ADP-ribose)
(PAR) polymer-induced cell death. Proc. Natl. Acad. Sci. USA 103, 18314–
18319.
Zong, W.X., Ditsworth, D., Bauer, D.E., Wang, Z.Q., and Thompson, C.B.
(2004). Alkylating DNA damage stimulates a regulated form of necrotic cell
death. Genes Dev. 18, 1272–1282.ports 8, 1819–1831, September 25, 2014 ª2014 The Authors 1831
